MA27809A1 - Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase - Google Patents

Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase

Info

Publication number
MA27809A1
MA27809A1 MA28613A MA28613A MA27809A1 MA 27809 A1 MA27809 A1 MA 27809A1 MA 28613 A MA28613 A MA 28613A MA 28613 A MA28613 A MA 28613A MA 27809 A1 MA27809 A1 MA 27809A1
Authority
MA
Morocco
Prior art keywords
phosphorylase
glycogen
pyrrolopyridine
carboxylic acid
acid amides
Prior art date
Application number
MA28613A
Other languages
English (en)
Inventor
Stuart Edward Bradley
Thomas Martin Krulle
Peter John Murray
Martin James Procter
Robert John Rowley
Smith Colin Peter Sambrook
Gerard Hugh Thomas
Karen Lesley Schofield
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA27809A1 publication Critical patent/MA27809A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogène-phosphorylase Les composés représentés par la formule (I) : ou leurs sels pharmaceutiquement acceptables, sont des inhibiteurs de la glycogène-phosphorylase et sont utiles dans le traitement prophylactique ou thérapeutique du diabète, de l'hyperglycémie, de l'hypercholestérolémie, de l??hyperinsulinémie, de l'hyperlipidémie, de l'hypertension, de l'athérosclérose ou d'une ischémie tissulaire, par exemple de l'ischémie myocardique, et comme cardioprotecteurs.
MA28613A 2003-05-21 2005-11-21 Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase MA27809A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US55125604P 2004-03-08 2004-03-08

Publications (1)

Publication Number Publication Date
MA27809A1 true MA27809A1 (fr) 2006-03-01

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28613A MA27809A1 (fr) 2003-05-21 2005-11-21 Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase

Country Status (16)

Country Link
EP (1) EP1636224B1 (fr)
JP (2) JP2006528702A (fr)
KR (1) KR101120935B1 (fr)
AT (1) ATE473974T1 (fr)
AU (1) AU2004240946B8 (fr)
BR (1) BRPI0410445B1 (fr)
CA (1) CA2525502C (fr)
DE (1) DE602004028122D1 (fr)
EA (1) EA009215B1 (fr)
IL (1) IL171851A (fr)
MA (1) MA27809A1 (fr)
MX (1) MXPA05012547A (fr)
NO (1) NO332265B1 (fr)
NZ (1) NZ543482A (fr)
UA (1) UA84146C2 (fr)
WO (1) WO2004104001A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
EP1685102A4 (fr) * 2003-11-12 2008-08-20 Lg Life Sciences Ltd Agonistes du recepteur de la melanocortine
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US7608627B2 (en) * 2004-04-05 2009-10-27 Takeda Pharmaceutical Company Limited 6-azaindole compound
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
JP2008521874A (ja) 2004-12-02 2008-06-26 プロシディオン・リミテッド グリコーゲンホスホリラーゼのインヒビターとして有用なピロロピリジン−２−カルボン酸アミド誘導体
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
ES2344077T3 (es) * 2005-12-16 2010-08-17 F.Hoffmann-La Roche Ag Derivados de pirrolo(2,3-b)piridina como moduladores del receptor h3.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
CA2738929A1 (fr) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Composes indole a substitution heteroaryle utilises comme inhibiteurs de mmp-13
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CN103582630B (zh) 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
BR112015003098A2 (pt) 2012-08-17 2017-08-22 Bayer Cropscience Ag Azaindolecarboxamidas e azaindoletiocarboxamidas como inseticidas e acaricidas.
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
WO2015091645A1 (fr) 2013-12-18 2015-06-25 Basf Se Composés d'azole transportant un substituant dérivé d'imine
CA3163206A1 (fr) * 2019-11-27 2021-06-03 Riken Inhibiteur de g9a
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
KR20230169977A (ko) * 2021-03-10 2023-12-18 빈시어 바이오사이언시스, 인크. Usp30 억제제 및 이의 용도
CN115745891B (zh) * 2022-11-10 2025-08-01 常州大学 吡唑衍生物在作为β2-肾上腺素受体拮抗剂的应用
WO2023165168A1 (fr) * 2022-10-27 2023-09-07 常州大学 APPLICATION D'UN DÉRIVÉ DE PYRAZOLE EN TANT QUE MODULATEUR, ANTAGONISTE ET AGONISTE ALLOSTÉRIQUE DU RÉCEPTEUR ADRÉNERGIQUE β2
CN115894373B (zh) * 2022-10-27 2025-08-01 常州大学 N-取代苄基吡唑衍生物在作为β2肾上腺素受体调节剂、拮抗剂和激动剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
EP0712844A4 (fr) * 1994-06-06 1996-11-06 Green Cross Corp Nouveau compose d'acide carboxylique a noyau fusionne ou sel de ce compose, et son utilisation en medecine
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
MY114711A (en) * 1995-06-06 2002-12-31 Pfizer Substituted n-(indole-2-carbonyl)-b-alanmamides and derivatives as antidiabetic agents
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
ATE257480T1 (de) * 1999-09-30 2004-01-15 Pfizer Prod Inc Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
WO2004039807A1 (fr) * 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine et derives de pyridoindolizine

Also Published As

Publication number Publication date
MXPA05012547A (es) 2006-05-25
EA009215B1 (ru) 2007-12-28
AU2004240946A1 (en) 2004-12-02
EP1636224B1 (fr) 2010-07-14
ATE473974T1 (de) 2010-07-15
IL171851A (en) 2011-08-31
NO20055305L (no) 2005-12-15
WO2004104001A2 (fr) 2004-12-02
EP1636224A2 (fr) 2006-03-22
EA200501645A1 (ru) 2006-06-30
JP2006528702A (ja) 2006-12-21
BRPI0410445A (pt) 2006-05-30
AU2004240946B2 (en) 2011-09-08
NO20055305D0 (no) 2005-11-10
JP2011252005A (ja) 2011-12-15
UA84146C2 (ru) 2008-09-25
CA2525502A1 (fr) 2004-12-02
DE602004028122D1 (de) 2010-08-26
KR20060069792A (ko) 2006-06-22
KR101120935B1 (ko) 2012-03-05
BRPI0410445B1 (pt) 2017-11-28
CA2525502C (fr) 2012-12-18
NZ543482A (en) 2009-02-28
WO2004104001A3 (fr) 2005-03-03
JP5669691B2 (ja) 2015-02-12
AU2004240946B8 (en) 2012-01-12
NO332265B1 (no) 2012-08-13

Similar Documents

Publication Publication Date Title
MA27809A1 (fr) Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
JO2282B1 (en) Oxazole derivatives
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
MA27040A1 (fr) Nucleosides substitues en 4'
ATE384058T1 (de) Thiazolderivate
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
NO20053498L (no) Derivater av aryl-quinaolin/aryl-2-amino-fenylmetanon som fremmer frigivelse av paratyroidhormon
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
ATE483708T1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
PT992509E (pt) Novos derivados macrolidos
SE9902267D0 (sv) New compounds
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
BRPI0411245A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv
AU2566101A (en) Compounds and methods for the treatment of pain
PT1280527E (pt) Utilizacao de derivados de acriloil distamicina no tratamento de tumores associados a niveis de glutationa elevados
WO2005085194A3 (fr) Hydrazides d'acide indole-2-carboxylique
TW200509941A (en) Pharmaceutical solution composition
PT952157E (pt) Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
UA81617C2 (en) Chalcone derivatives and their use